Literature DB >> 19903100

Properties and growth of human bone marrow mesenchymal stromal cells cultivated in different media.

Karolina Turnovcova1, Katerina Ruzickova, Vaclav Vanecek, Eva Sykova, Pavla Jendelova.   

Abstract

BACKGROUND AIMS: Human mesenchymal stromal cells (hMSC) are a promising tool for future clinical application, but their use requires rapid cell expansion in media suitable for clinical use. Therefore, we tested the influence of several culture media on colony formation, population doubling (PD) time, cell cycle and surface marker expression.
METHODS: hMSC isolated from human bone marrow (BM) obtained from healthy donors were seeded and expanded in different culture media: alpha-minimum essential medium (MEM) supplemented with 2.5%, 5%, 10% or 20% fetal bovine serum (FBS), 5% or 10% human cord blood serum (hCBS), 5% or 10% human blood serum from AB adult donors (hABS), or mesenchymal stem cell growth medium (MSCGM). The number, diameter and total area of the colonies formed and PD time were determined, and the cell cycle and 16 surface markers were analyzed.
RESULTS: Colony-forming efficiency was best in alpha-MEM/hCBS and alpha-MEM/hABS, good in MSCGM and worst in alpha-MEM/FBS. The shortest PD time was achieved in media enriched with human sera or MSCGM, while the time was increased in alpha-MEM/FBS. The largest proliferating fraction was seen in MSCGM followed by media enriched with human sera; the fraction was smallest in alpha-MEM/FBS. Staining for CD34, CD45, CD235a and CD271 was negative, while that for CD29, CD44, CD73, CD90, CD105 and human leukocyte antigen (HLA)-A, -B, -C was positive in all media tested. Media with human serum did not adversely affect the differentiation potential of hMSC, and differentiation into osteoblasts was enhanced.
CONCLUSIONS: The choice of serum influences hMSC expansion and cell properties; alpha-MEM supplemented with hABS seems to be a promising candidate for clinical use.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903100     DOI: 10.3109/14653240903188947

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  29 in total

Review 1.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

2.  Transplantation of predifferentiated adipose-derived stromal cells for the treatment of spinal cord injury.

Authors:  David Arboleda; Serhiy Forostyak; Pavla Jendelova; Dana Marekova; Takashi Amemori; Helena Pivonkova; Katarina Masinova; Eva Sykova
Journal:  Cell Mol Neurobiol       Date:  2011-06-01       Impact factor: 5.046

Review 3.  Adult human adipose tissue contains several types of multipotent cells.

Authors:  Tiziano Tallone; Claudio Realini; Andreas Böhmler; Christopher Kornfeld; Giuseppe Vassalli; Tiziano Moccetti; Silvana Bardelli; Gianni Soldati
Journal:  J Cardiovasc Transl Res       Date:  2011-02-15       Impact factor: 4.132

Review 4.  [Cell therapy in bone-healing disorders].

Authors:  M Jäger; P Hernigou; C Zilkens; M Herten; J Fischer; R Krauspe
Journal:  Orthopade       Date:  2010-04       Impact factor: 1.087

5.  Expression of blood group genes by mesenchymal stem cells.

Authors:  Richard Schäfer; Martina Schnaidt; Roland A Klaffschenkel; Georg Siegel; Michael Schüle; Maria Anna Rädlein; Ursula Hermanutz-Klein; Miriam Ayturan; Marine Buadze; Christoph Gassner; Lusine Danielyan; Torsten Kluba; Hinnak Northoff; Willy A Flegel
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

Review 6.  Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality.

Authors:  Riccardo Calafiore; Giuseppe Basta
Journal:  Am J Stem Cells       Date:  2015-03-15

7.  Differentiation of human mesenchymal stem cell spheroids under microgravity conditions.

Authors:  Wolfgang H Cerwinka; Starlette M Sharp; Barbara D Boyan; Haiyen E Zhau; Leland W K Chung; Clayton Yates
Journal:  Cell Regen (Lond)       Date:  2012-06-28

Review 8.  Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Authors:  Melania Lo Iacono; Rita Anzalone; Giampiero La Rocca; Elena Baiamonte; Aurelio Maggio; Santina Acuto
Journal:  Stem Cell Rev Rep       Date:  2017-02       Impact factor: 5.739

9.  The Transplantation of hBM-MSCs Increases Bone Neo-Formation and Preserves Hearing Function in the Treatment of Temporal Bone Defects - on the Experience of Two Month Follow Up.

Authors:  Lukáš Školoudík; Viktor Chrobok; Zuzana Kočí; Jiří Popelář; Josef Syka; Jan Laco; Alžběta Filipová; Eva Syková; Stanislav Filip
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

10.  The combination of mesenchymal stem cells and a bone scaffold in the treatment of vertebral body defects.

Authors:  Václav Vaněček; Karel Klíma; Aleš Kohout; René Foltán; Ondřej Jiroušek; Jiří Šedý; Jan Štulík; Eva Syková; Pavla Jendelová
Journal:  Eur Spine J       Date:  2013-09-07       Impact factor: 3.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.